放疗联合免疫治疗的生物学基础及研究进展

尹利梅; 庞琛; 卢铀

doi:10.3969/j.issn.1000-8179.2017.22.296

放疗联合免疫治疗的生物学基础及研究进展

doi: 10.3969/j.issn.1000-8179.2017.22.296

四川大学华西医院胸部肿瘤科（成都市610041）

基金项目:

国家自然科学基金项目 81672982

四川省科技厅应用基础研究计划项目 2016JY0050

详细信息

作者简介:
尹利梅专业方向为肺癌的放射治疗与免疫治疗。E-mail：limei-yin@foxmail.com

通讯作者:
卢铀 radyoulu@hotmail.com

计量
- 文章访问数: 86
- HTML全文浏览量: 104
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2017-03-14
- 修回日期: 2017-07-05
- 刊出日期: 2017-11-30

Biological foundation and research progress on radiotherapy combined with immunotherapy

Department of Thoracic Oncology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu 610041, China

Funds:

the National Natural Science Foundation of China 81672982

the Applied Basic Research Programs of Science and Technology Department of Sichuan Province 2016JY0050

More Information

Corresponding author: You LU; E-mail: radyoulu@hotmail.com

摘要

摘要: 研究发现放疗能促进肿瘤细胞免疫原性死亡，并经肿瘤抗原呈递和特异性T细胞免疫应答过程来杀伤肿瘤，甚至产生系统性抗肿瘤免疫反应，引起照射野外肿瘤缩小，上述现象被称为放疗远位效应。尽管放疗的临床远位效应已有报道，许多基础及转化性研究也证实其发生存在一定的生物学基础，但放疗远位效应更多地表现为亚临床效应，难以达到临床客观疗效。目前，抗PD-1/PD-L1抗体免疫治疗在临床肿瘤研究中展示出明显而确切的疗效，是临床中局部放疗联合免疫治疗的新治疗模式。但是，这种新治疗模式的临床实践，应当基于能够产生远位效应的放疗分割模式以及最佳的联合时机，最终达到全身抗肿瘤免疫反应的协同疗效。
- 肿瘤 /
- 放射治疗 /
- 免疫治疗 /
- 远位效应
Abstract: Numerous studies revealed that radiation can promote the immunogenic cell death, enhance the immune response of tumor-antigen-specific T cells, and induce systematic antitumor immunity, which may result in abscopal effect. Abscopal effect refers to the regression of non-irradiated metastatic lesions distant from the primary tumor site that is directly subjected to irradiation. Despite that abscopal effect has been clinically reported and that many preclinical studies have confirmed its biological basis, abscopal effect remains a subclinical phenomenon, in which objective efficacy is difficult to obtain. Currently, the anti-PD-1/PD-L1 therapy in clinical applications shows a clear and definite curative effect, thereby making local radiotherapy combined with immunotherapy a new treatment pattern. However, the clinical practice of this new mode should be based on appropriate dose and fraction and the most suitable temporal combination to achieve the synergic antitumor immune response.
- tumor /
- radiotherapy /
- immunotherapy /
- abscopal effect

HTML全文

参考文献(36)

[1]	Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age[J]. Ann Transl Med, 2016, 4(6):118. doi: 10.21037/atm
[2]	Mole RH. Whole body irradiation; radiobiology or medicine[J]? Br J Radiol, 1953, 26(305):234-241. doi: 10.1259/0007-1285-26-305-234
[3]	Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin, 2017, 67(1):65-85. doi: 10.3322/caac.21358
[4]	Levy A, Chargari C, Marabelle A, et al. Can immunostimulatory agents enhance the abscopal effect of radiotherapy[J]? Eur J Cancer, 2016, (62):36-43. https://www.sciencedirect.com/science/article/pii/S0959804916320299
[5]	Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. N Engl J Med, 2012, 366(10):925-931. doi: 10.1056/NEJMoa1112824
[6]	Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer[J]. Cancer Immunol Res, 2013, 1(6):365-372. doi: 10.1158/2326-6066.CIR-13-0115
[7]	Van de Walle M, Demol J, Staelens L, et al. Abscopal effect in metastatic renal cell carcinoma[J]. Acta Clin Belg, 2016:1-5. https://biblio.ugent.be/publication/8521521
[8]	Reynders K, Illidge T, Siva S, et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant[J]. Cancer Treat Rev, 2015, 41(6):503-510. doi: 10.1016/j.ctrv.2015.03.011
[9]	Frey B, Rubner Y, Wunderlich R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies[J]. Curr Med Chem, 2012, 19(12):1751-1764. doi: 10.2174/092986712800099811
[10]	Norian LA, Rodriguez PC, O'Mara LA, et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8⁺ T cell function via L-arginine metabolism[J]. Cancer Res, 2009, 69(7):3086-3094. doi: 10.1158/0008-5472.CAN-08-2826
[11]	Kanegasaki S, Matsushima K, Shiraishi K, et al. Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy[J]. Cancer Res, 2014, 74(18): 5070-5078. doi: 10.1158/0008-5472.CAN-14-0551
[12]	Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation[J]. Cancer Bio Radio, 2012, 27(1):12-22. doi: 10.1089/cbr.2012.1202
[13]	Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer[J]. Cancer Res, 1999, 59(24):6028-6032. https://www.ncbi.nlm.nih.gov/pubmed/10626784#
[14]	Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J]. Int J Radiat Oncol Biol Phys, 2004, 58(3):862-870. doi: 10.1016/j.ijrobp.2003.09.012
[15]	Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proofof-principle trial[J]. The Lancet Oncol, 2015, 16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6
[16]	Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer[J]. Clin Cancer Res, 2005, 11(2 Pt 1):728-734. https://www.ncbi.nlm.nih.gov/pubmed/15701862
[17]	Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009, 15(17):5379-5388. doi: 10.1158/1078-0432.CCR-09-0265
[18]	Wu L, Wu MO, De la Maza L, et al. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model[J]. Oncotarget, 2015, 6(14):12468-12480. doi: 10.18632/oncotarget.v6i14
[19]	Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2):687-695. doi: 10.1172/JCI67313
[20]	Park SS, Dong H, Liu X, et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect[J]. Cancer Immunol Res, 2015, 3(6):610-619. doi: 10.1158/2326-6066.CIR-14-0138
[21]	Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer [J]. Nature, 2015, 520(7547):373-377. doi: 10.1038/nature14292
[22]	Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumorspecific effector CD8+ T cells via dendritic cell activation[J]. J Immunol, 2012, 189(2):558-566. doi: 10.4049/jimmunol.1200563
[23]	Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity[J]. Cancer Res, 2015, 75(11):2232-2242. doi: 10.1158/0008-5472.CAN-14-3511
[24]	Siva S, MacManus MP, Martin RF, et al. Abscopal effects of radiation therapy: a clinical review for the radiobiologist[J]. Cancer Lett, 2015, 356(1):82-90. doi: 10.1016/j.canlet.2013.09.018
[25]	Yovino S, Kleinberg L, Grossman SA, et al. The etiology of treatmentrelated lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells[J]. Cancer Invest, 2013, 31(2):140-144. doi: 10.3109/07357907.2012.762780
[26]	Popp I, Grosu AL, Niedermann G, et al. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications[J]. Radiother Oncol, 2016, 120(2):185-194. doi: 10.1016/j.radonc.2016.07.013
[27]	Palma DA, Louie AV, Rodrigues GB. New Strategies in Stereotactic Radiotherapy for Oligometastases[J]. Clin Cancer Res, 2015, 21(23): 5198-5204. doi: 10.1158/1078-0432.CCR-15-0822
[28]	Lan J, Li R, Deng L, et al. Hypofractionated radiotherapy slashes the immune-suppressive activity on CD8⁺T cell in tumor microenvironment[J]. Int J of Radiat Oncol Biol Phys, 2016, (96):S86. http://www.redjournal.org/article/S0360-3016(16)30543-0/fulltext
[29]	Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach[J]? Nat Rev Clin Oncol, 2016, 13(8):516-524. doi: 10.1038/nrclinonc.2016.30
[30]	Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53[J]. Cancer Res, 2003, 63(8): 1990-1993. https://www.ncbi.nlm.nih.gov/pubmed/12702593
[31]	Martin OA, Anderson RL, Narayan K, et al. Does the mobilization of circulating tumour cells during cancer therapy cause metastasis[J]? Nat Rev Clin Oncol, 2017, 14(1):32-44. https://www.researchgate.net/publication/306401849_Does_the...
[32]	Vilalta M, Rafat M, Graves EE. Effects of radiation on metastasis and tumor cell migration[J]. Cell Mol Life Sci, 2016, 73(16):2999-3007. doi: 10.1007/s00018-016-2210-5
[33]	Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-beta Paradox to EMT-MET programs[J]. Cancer Lett, 2013, 341(1):30-40. doi: 10.1016/j.canlet.2013.02.048
[34]	Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18):1749-1755. doi: 10.1056/NEJMoa1609214
[35]	Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015, 373(3):288-290. doi: 10.1056/NEJMc1505197
[36]	Xue JX, Du SS, Lu Y, et al. Anti-PD-1 treatment may potentiate the radiation-induced lung injury[J]. Proceed Am Associ Cancer Res, 2017, (58):936. doi: 10.1186/s40425-017-0261-2